Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Gastric Cancer After D2 Lymph Node Dissection Clinical Trial

Official title: Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study

Status Completed

Clinical Trial Summary

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gastric Cancer After D2 Lymph Node Dissection
• Stomach Neoplasms

• NCT number: NCT01914692
• Study type: Interventional
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Status: Completed
• Phase: Phase 4
• Start date: January 2013
• Completion date: July 2013